Obesity-Cancer Link: It’s Worse Than You Think
Obesity-Cancer Link: It’s Worse Than You Think
From WebMD: Cancer deaths are dropping overall, but not the ones linked to obesity. That’s what mounting evidence now shows. A sweeping new report on U.S. cancer trends, published in April, revealed that cancers linked to obesity are becoming more common. Another study, presented in July at the Endocrine Society Annual Meeting in San Francisco, found that deaths from […]
Obesity-associated cancers tripled nationwide over past two decades
SAN FRANCISCO—Cancer deaths linked to obesity have tripled in the United States over the past two decades, according to a study being presented Sunday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif. The study, which examined more than 33,000 deaths from obesity-associated cancers, revealed sharp increases in cancer deaths, especially among […]
Evexomostat Phase 1 Clinical Safety Study in Late-Stage Cancer Patients
2025 Cornelius A phase 1 safety study of evexomostat in patients with late-stage cancer
$1.2M Grant Awarded for Groundbreaking Prostate Cancer Research on SynDevRx MetAP2 Inhibitor ‘Evexomostat’
Cambridge, MA (USA) and Brisbane (Australia) – Queensland University of Technology (QUT) in Brisbane, Australia, together with SynDevRx, Inc., a leader in polymer-drug conjugates for cancer and for metabolic dysfunction are honored to announce the receipt of a $1.2 million grant from the US Department of Defense (DoD) for continued research on evexomostat, SynDevRx’s novel […]
AACR Journal MCT Publishes Initial Disclosure Article on Evexomostat/SDX-7320
Pharmacological Characterization of SDX-7320/Evexomostat: a Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-Tumor and Anti-Metastatic Activity Methionine aminopeptidase type 2 (MetAP2) is a ubiquitous, evolutionarily conserved metalloprotease fundamental to protein biosynthesis which catalyzes removal of the N-terminal methionine residue from nascent polypeptides. MetAP2 is an attractive target for cancer therapeutics based upon its over-expression in […]
Amelia-1 Clinical Trial Fully Open To Recruitment, 1st Patient Data on Combination Study with PI3K Inhibitor and SERD
SynDevRx, Inc. today announced the opening of the Amelia-1 study and data from the first patient treated in its Phase 1b/2 clinical study testing the novel MetAP2 inhibitor evexomostat (aka SDX-7320) in combination with the PI3K inhibitor alpelisib (Piqray®) and the estrogen receptor degrader (SERD) drug fulvestrant (Faslodex®) in breast cancer patients with metastatic disease […]
New Experimental Treatment for Prostate Cancer Revealed at AACR
SDX AACR 2023 poster 05Apr 2023.pptx PRESS RELEASE • APR 14, 2023 08:00 EDT Evexomostat (SDX-7320) shows potent anti-tumor effects in pre-clinical models of prostate cancer, including castration-resistant. New research data to be presented at AACR 2023 in Orlando, FL
SynDevRx Joins ‘Touch – The Black Breast Cancer Alliance’ CEO Ricki Fairley in Metabo-Oncology Podcast – Wed. Oct 5, 2022 at 6:00 PM
Aug. 31, 2022 – SynDevRx Presents Scientific Poster on Anti-Fibrosis Data with Evexomostat at the 2022 IPF Conference in Boston
Aug. 31, 2022 – SynDevRx, Inc., a clinical-stage biotechnology company leading the development of treatments for obesity-accelerated cancers, today announced the presentation of new scientific data on its lead compound evexomostat (SDX-7320) in a series of fibrosis models demonstrating potent anti-fibrosis data monotherapy and in combination with the standard of care therapy nintedanib. Evexomostat significantly […]
New Phase 1b/2 Clinical Research Study with SynDevRx Drug Evexomostat (SDX-7320) Announced for Triple-Negative Breast Cancer Patients with Baseline Insulin Resistance
SynDevRx, Inc. today announced the opening of a first-of-its-kind Phase 1b/2 study for patients with triple-negative breast cancer and baseline insulin resistance, testing the novel drug evexomostat (SDX-7320) in combination with standard-of-care treatment Halaven (eribulin, Esai). Evexomostat is among the first anti-cancer therapeutics being developed specifically for cancer patients with baseline metabolic dysfunction (obesity, type […]